Published in Medical Letter on the CDC and FDA, January 16th, 2005
Neoadjuvant treatments are administered prior to surgery and represent a novel and increasingly applied approach to make surgical tumor resections either more complete improving outcomes or less invasive facilitating breast conservation. Objective clinical responses with a greater than 50% reduction in tumor size were seen following the combined therapy in all of the patients.
Complete tumor removal by subsequent surgery was achieved in 100% of the patients. The results of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.